MART-1 T cell receptors

• US 8,119,772 B2
• Filed: 09/28/2007
• Issued: 02/21/2012
• Est. Priority Date: 09/29/2006
• Status: Active Grant

• Current Assignee: California Institute of Technology, Regents of the University of California (University of California)
• Original Assignee: California Institute of Technology, Regents of the University of California (University of California)
• Inventors: Yang, Lili, Baltimore, David, Economou, James, Ribas, Antoni, Wang, Pin
• Primary Examiner(s): SKELDING, ZACHARY S
• Application Number:
  US11/864,841
• Publication Number:
  US 20080199424A1
• Time in Patent Office: 1,607 Days
• Field of Search: None
• US Class Current: 530/381
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Abstract

T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma.

Claims

1. An isolated polypeptide comprising an amino acid sequence with at least 95% sequence identity to SEQ ID NO:

3, wherein the variable region of the polypeptide consists of SEQ ID NO;

4.

2. The isolated polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

3.

5. The isolated polypeptide of claim 1, wherein the polypeptide comprises an amino acid sequence with at least 99% sequence identity to SEQ ID NO:

3.

6. The isolated polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:

3.

3. A transfected cell comprising:

a T-cell receptor comprising an α

subunit with at least 95% sequence identity to SEQ ID NO;

3 and a β

subunit with at least 95% sequence identity to SEQ ID NO;

7, wherein the variable region of the α

subunit consists of SEQ ID NO;

4, and wherein the variable region of the β

subunit consists of SEQ ID NO;

8.

7. The transfected cell of claim 3, wherein the α

subunit has at least 99% sequence identity to SEQ ID NO;

3.

8. The transfected cell of claim 3, wherein the α

subunit consists of the amino acid sequence of SEQ ID NO;

3.

9. The transfected cell of claim 3, wherein the β

subunit has at least 99% sequence identity to SEQ ID NO;

7.

10. The transfected cell of claim 3, wherein the β

subunit consists of the amino acid sequence of SEQ ID NO;

7.

4. A T-cell receptor, comprising:

an α

subunit; and

a β

subunit,

wherein the α

subunit comprises an amino acid sequence with at least 95% sequence identity to SEQ ID NO;

3 and the β

subunit comprises an amino acid with at least 95% sequence identity to SEQ ID NO;

7, wherein the variable region of the α

subunit consists of SEQ ID NO;

4, and wherein the variable region of the β

subunit consists of SEQ ID NO;

8.

11. The T-cell receptor of claim 4, wherein the α

subunit has at least 99% sequence identity to SEQ ID NO;

3.

12. The T-cell receptor of claim 4, wherein the α

subunit consists of the amino acid sequence of SEQ ID NO;

3.

13. The T-cell receptor of claim 4, wherein the β

subunit has at least 99% sequence identity to SEQ ID NO;

7.

14. The T-cell receptor of claim 4, wherein the β

subunit consists of the amino acid sequence of SEQ ID NO;

7.